Avantect Ovarian Cancer Test

ORDER TEST

Avantect Ovarian Cancer Test

Early Detection of Ovarian Cancer is Critical

Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths among women. Ovarian cancer is often diagnosed too late as four out of five ovarian cancer patients are diagnosed with advanced disease. Early intervention can significantly improve survival rates and is crucial for women who are known to be at higher risk for the disease. ClearNote Health has developed the Avantect Ovarian Cancer Test for women with high risk for ovarian cancer who carry genetic predispositions such as BRCA1, BRCA2 mutations or have a first-degree family member with ovarian cancer.1,2 

Purpose-built

The Avantect Ovarian Cancer Test is specifically designed for the early detection of ovarian cancer

Easy to use

A routine blood draw makes it easy to incorporate the Avantect test into clinical management protocols for high-risk patients

Actionable report

Clear information about whether signals are detected, with recommendations for next steps

Seeing beyond the code

Epigenomic changes are present in the earliest stages of cancer and 5-hydroxymethylcytosine (5hmC), a chemical modification of DNA, can be used as a targeted biomarker to identify these changes.

Using the latest epigenomic and genomic science, the Avantect test may reveal the emergence of cancer cells early. Its streamlined technology uses a combination of 5hmC profiling and whole-genome sequencing in a single assay to enable a deep look into cancer biology.3,4,5,6

VIEW VIDEO

Get started with Avantect

See how easy it is to use the Avantect test with your high-risk patients.

REGISTER AN ACCOUNT

Important information

The Avantect Ovarian Cancer Test is an early detection test. The test does not establish a diagnosis of ovarian cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of ovarian cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all ovarian cancers will be detected. Some patients with ovarian cancer may have a “Signal not detected” result. Some patients without ovarian cancer may have a “Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no ovarian cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.

The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).

References and notes

  1. Ovarian Cancer Risk Factors. (Accessed 1/25/2024, at https://www.cancer.org/cancer/types/ovarian-cancer/causes-risks-prevention/risk-factors.html.)
  2. Ovarian Cancer – StatPearls – NCBI Bookshelf (nih.gov)
  3. Guler GD, Ning Y, Ku CJ, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020;11:5270.
  4. Song CX, Yin S, Ma L, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017;27:1231–1242.
  5. Haan D, Bergamaschi A, Friedl V, et al. Epigenomic Blood-Based Early Detection of Pancreatic Cancer Employing Cell-Free DNA. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1802-1809.
  6. Data on file